Open AccessPhase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Author(s) -
Sikander Ailawadhi,
Aneel Paulus,
Victoria R. Alegria,
Betsy LaPlant,
Muhamad Alhaj Moustafa,
Dustin Chapin,
Keisha Jackson,
Prachi Jani,
Salman Ahmed,
Brett Edwards,
Alak Manna,
Vivek Roy,
Taimur Sher,
Asher ChananKhan
Publication year - 2019
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood-2019-128233
Subject(s) - lenalidomide , medicine , neutropenia , multiple myeloma , pomalidomide , bendamustine , gastroenterology , dexamethasone , absolute neutrophil count , febrile neutropenia , pharmacology , rituximab , chemotherapy , lymphoma
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom